Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
- Posted on June 9, 2026
- By Forbes
- 0 Views
- 1 min read
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
Half of U.S. employers and health plans are balking at paying for GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and obesity treatment, a new report shows.